GSK, US government in $196m anthrax treatment deal
GSK has announced a new $196 million, four year contract with the US Government to provide 60,000 doses of inhalation anthrax treatment, raxibacumab, as a “counter measure against a potential bioterrorist attack“.
The global pharma company will supply raxibacumab to the Biomedical Advanced Research and Development Authority (BARDA), which is part of the US Department of Health and Human Services (HHS.
Anthrax has been classified as a Category A biothreat by the US Centers for Disease Control and Prevention (CDC) since 2001, as it poses a severe threat to public health and safety. Anthrax is one of the most likely agents to be used in a bioterrorist attack as its spores are easily found in nature and can be produced in a lab. It can be released into the environment quietly and remain there for a long time.
“We have been collaborating with BARDA for a number of years and raxibacumab is now an important part of the US Government’s emergency counter measures against bioterrorism. Through this agreement, we are proud to be helping protect US citizens against such threats.”
Sheri Mullen, Vice President of Immunology & Rare Diseases, US Pharmaceuticals, GSK.
Mary Kerr, global commercial lead for infectious diseases at GSK.
GlaxoSmithkline signs $196 million US anthrax treatment deal (Economic Times)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.